Results 61 to 70 of about 13,744 (204)

Flecainide in clinical practice

open access: yesCardiology Journal, 2023
Flecainide, similar to encainide and propafenone, is IC class antiarrhythmic, inhibiting Nav1.5 sodium channels in heart muscle cells and modulates cardiac conduction. Despite its over 40-year presence in clinical practice, strong evidence and well-known
Mikołaj Basza   +14 more
doaj   +1 more source

Clinical Practice Guidelines for paroxysmal supraventricular tachycardia.

open access: yesMedisur, 2009
Clinical Practice Guidelines for paroxysmal supraventricular tachycardia. These are arrhythmias in which structures placed above the bifurcation of the bundle of His are involved; characterized by tachycardia with abrupt starting and ending.
Brandy Viera Valdés   +3 more
doaj   +2 more sources

A Large, Real‐World Cohort Analysis of Arrhythmia Detection and Therapeutic Interventions in Patients With Insertable Cardiac Monitors and Long‐Term Monitoring

open access: yesJournal of Cardiovascular Electrophysiology, Volume 37, Issue 2, Page 359-373, February 2026.
ICM arrhythmia detection and therapeutic interventions. ABSTRACT Background Insertable cardiac monitors (ICMs) provide long‐term continuous monitoring for arrhythmia diagnosis and management for various clinical indications. However, little data exists on comprehensive real‐world arrhythmia diagnostic yield and therapy rates in patients indicated for ...
Sandeep A. Saha   +8 more
wiley   +1 more source

Effects of Landiolol Hydrochloride on Intractable Tachyarrhythmia After Pediatric Cardiac Surgery [PDF]

open access: yes, 2013
BackgroundWhile β-blockers can be effective in controlling tachyarrhythmias after pediatric cardiac surgery, a negative inotropic influence sometimes complicates their use.
Abe Masakazu   +12 more
core   +1 more source

Management of Ablation‐Refractory Atrial Fibrillation During Pregnancy

open access: yesCase Reports in Medicine, Volume 2026, Issue 1, 2026.
Development of new atrial fibrillation (AF) is uncommon in pregnancy with an incidence of 0.03%. The occurrence of drug‐refractory AF during pregnancy in individuals with structurally normal hearts is even rarer, and there are no reports of ablation‐refractory AF during pregnancy in the literature.
Faris Abu Za’nouneh   +5 more
wiley   +1 more source

Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases [PDF]

open access: yes, 2016
Cardiovascular diseases are the leading cause of death in the world. Coronary artery diseases, atrial fibrillation or hypertensive heart disease, are among the most important cardiovascular disorders. Hypertension represents a significant risk factor for
Alejandro de la Sierra   +5 more
core   +4 more sources

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 12, Page 3461-3470, December 2025.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon   +10 more
wiley   +1 more source

Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real‐World Analysis

open access: yesCancer Medicine, Volume 14, Issue 24, December 2025.
ABSTRACT Background Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non‐cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.
Wei Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy